IMUX
ImmunicFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that Immunic now has a meaningfully improved cash position after the February 2026 private placement, removing the most immediate financing pressure, while the late-2026 ENSURE readout offers substantial re-rating potential if efficacy and safety support the RMS thesis [#10-K-2026-02-26].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.2.
What can break
Future capital structure complexity, including warrant-related overhang, could restrain upside even after financing.
Momentum
79
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.80 · Bear $0.35
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $43.22
Why
Momentum79 · Δ7d -2.2
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
-16.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 78.5 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$204.32M
Beta
1.57
Shares Out
13.62M
P/E (TTM) · Derived
-2.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.95
Rev YoY
-
EPS YoY
-57.0%
Gross Margin
-
Op Margin
-
Net Debt
-$14.91M
Current Ratio
4.92
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology